Brain Cancer
Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, requiring highly specialized models that accurately recapitulate tumor biology, invasiveness, and CNS constraints.
Powered Research performs preclinical studies using human brain cancer PDX and CDX tumor cells in surgical implantation, dosing, monitoring and comprehensive endpoint analysis under one experienced team. This unified approach ensures consistent execution, rapid turnaround, and high-quality, decision-ready datasets.
We develop and evaluate GBM therapeutics using clinically relevant in-vivo models, including stereotactic intracranial and subcutaneous implantation techniques.
As illustrated on page 5 of our oncology brochure, these models are supported by robust in vitro platforms (monolayer, spheroids, neurospheres) and flexible dosing routes (intracranial, intravenous, intraperitoneal, intrathecal), enabling tailored study designs aligned with your therapeutic strategy.
Capabilities
-
Orthotopic (intracranial) and subcutaneous glioblastoma and astrocytoma models
-
Stereotactic implantation of human cells
-
3D cell culture systems (spheroids, neurospheres)
-
Flexible dosing routes aligned with CNS delivery strategies
-
In vivo imaging (IVIS) and in-life assessments
-
Histopathology, IHC, IF, and molecular analyses (qPCR)
-
Flow cytometry and immune profiling of tumor microenvironment
Advance your glioblastoma program with translationally relevant models and integrated data.
Contact Powered Research to design your next brain cancer preclinical study.